Form 4: Stoke Therapeutics Chief Medical Officer Sells Over 8,000 Shares Under Pre-Arranged Trading Plan

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 8,216 shares of common stock in early June 2025, pursuant to a Rule 10b5-1 trading plan established in December 2024.

Summary

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (STOK), reported sales of common stock.
• On June 2, 2025, Mr. Ticho sold 1,745 shares of common stock at a price of $10.00 per share.
• On June 3, 2025, an additional 6,471 shares of common stock were sold at a weighted average price of $10.0282 per share, with individual transactions ranging from $10.00 to $10.07.
• The total number of shares sold across both transactions is 8,216.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Mr. Ticho on December 11, 2024.
• Following these sales, Mr. Ticho's direct beneficial ownership of common stock stands at 25,782 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can be perceived negatively, the fact that these sales were executed under a pre-arranged Rule 10b5-1 trading plan mitigates concerns about the insider's immediate view of the company's prospects, as the decision to sell was made months in advance.

Positives

• The stock sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, which indicates the transactions were scheduled in advance and not based on immediate, non-public information.

Negatives

• The Chief Medical Officer reduced his direct beneficial ownership in the company by 8,216 shares, which can sometimes be perceived as a lack of confidence by investors, although mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The transactions reported were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

Industry Context

This document is an insider transaction report specific to Stoke Therapeutics and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may view the reduction in insider ownership with slight caution, though the pre-planned nature of the sales (Rule 10b5-1) generally lessens the negative signaling effect compared to discretionary sales.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Stock Sale, Beneficial Ownership, Rule 10b5-1, Chief Medical Officer